Zentalis Pharmaceuticals
ZNTL
110 hedge funds and large institutions have $1.15B invested in Zentalis Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 39 increasing their positions, 35 reducing their positions, and 9 closing their positions.
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
29% more call options, than puts
Call options by funds: $608K | Put options by funds: $471K
11% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 35
5% more funds holding
Funds holding: 105 → 110 (+5)
0.28% more ownership
Funds ownership: 112.51% → 112.79% (+0.28%)
11% less capital invested
Capital invested by funds: $1.29B → $1.15B (-$140M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$40.9M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$21.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$20.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$14M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$8.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$45M |
| 2 |
TCM
Tybourne Capital Management
Hong Kong
|
-$12.1M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.23M |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.11M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$4.05M |
ZNTL Hedge Fund Activity: Q1 2023 in Review
110 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q1 2023, worth a combined $1.15B — down 11% from $1.29B a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ZNTL positions and 9 closed out — a net gain of 5 holders — while 39 added to existing stakes and 35 trimmed.
The largest buyer was Woodline Partners, adding an estimated $40.9M. The largest seller was Avidity Partners Management, cutting an estimated $45M.
- 110 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q1 2023, up from 105 in Q4 2022.
- Funds reported $1.15B of Zentalis Pharmaceuticals stock for Q1 2023, down 11% quarter-over-quarter.
- 14 funds opened new Zentalis Pharmaceuticals positions in Q1 2023 and 9 closed out, a net change of +5 holders.
- The largest Zentalis Pharmaceuticals buyer in Q1 2023 was Woodline Partners, an estimated $40.9M added.
- The largest Zentalis Pharmaceuticals seller in Q1 2023 was Avidity Partners Management, an estimated $45M sold.
Based on aggregated 13F filings for Q1 2023.